9th Forum:

Collaboration for Success: Multi-Regional Clinical Development

 
May 25, 2018
12:30 PM - 4:00 PM
Yale Club Manhattan
 
 
Program
 

12:30-1:00 PM    Network Reception and Lunch  

 

1:00-1:10 PM       Opening Statement 

DoHyun Cho, PhD

Chairman, New York Health Forum

 

1:10-2:10 PM       Session 1 

“Current CRO M&A and Investment Trends"

The 1st session, “Current CRO M&A and Investment Trends” is designed to provide insights on “What would be the major trend and outlook for global CRO industry”. The CRO industry has seen a large number of mergers and acquisitions (M&A) over the past five years with key industry players becoming giants with more comprehensive coverage in terms of geography and specialties. These growing activities can be the result of several factors. In this session, we discuss the current trend and landscape of the CRO industry in various aspects, including rising global competition perspective.

 

  • Kimberly Ha (Founder, KKH Advisors) (Moderator)

  • Vincent Liu, PhD (Senior Advisor, Fosun Pharma)

  • David Blume (Managing Director, Edgemont Capital Partners)

  • John Bradley, MD (Managing Director, Torreya Partners)

 

2:10-2:30 PM     Networking Break

 

2:30-3:10 PM     Session 2

“Key Considerations for Successful Multi-Regional Clinical Trials” 

The 2nd session, “Key Considerations for successful Multi-Regional Clinical Trials” is designed to provide insights on significant growth of multi-regional clinical trials and ever-more increasing sponsor demands for successful study results in multi-national atmosphere. In this session, we discuss the current trends and landscapes of the CRO industry in the global setting and the requirements for a successful global development.

 

  • Joe McMenamin, MD, JD (EVP, W Medical Strategy Group) (Moderator)

  • Jeff Clark, MD, JD (Chief Licensing Officer, Enzychem Lifesciences)

  • Eunie Kim (Advisor, C&R Research)

  • John Choi, MS (Project Director, Enzychem Lifesciences)

 

3:10-3:50 PM      Session 3

“Quality and Tech in Clinical Development" 

The 3rd session, “Quality and Tech in Clinical Development” is designed to provide insights on art-of-the state technologies and methodologies associated with clinical development and human quality of life. In this session, we share expert views on technology assessments and disruptive technology related to machine learning and artificial intelligence in the clinical trials as well as the trending diagnostics tools to overcome unmet medical needs.

 

  • Surani Fernando (Editor, North America, Biopharm Insight) (Moderator)

  • Scott Howell, MD, MPH&TM, CPE (Chief Medical Officer, Tenet Diagnostics)

  • Anthony Chambers (Director, Life Sciences Practice, West Monroe Partners)

 

3:50-4:00 PM     Closing & Networking

 

DoHyun Cho, PhD

CEO and President, W Medical Strategy Group | Chairman, New York Health Forum

 

DoHyun Cho is the founder, president, and CEO of a U.S. consulting company W Medical Strategy Group. W Medical Strategy Group has 5 subsidiaries including World Korean Medical Journal (publication), New York Health Forum (Conference), W MediTech (medical device distribution), W MedicalCare (global healthcare agency), and Green Alley (skincare product distribution). He is also the Board of Director for Enzychem Lifesciences. Before establishing W Medical Strategy Group, DoHyun was the director general of Korea Health Industry Development Institute (KHIDI) USA in New York for six years, a specialized agency of Ministry of Health of Republic of Korea. He also served as a Board of Director for KOCHAM (Korean American Chamber of Commerce) and was actively involved in a bio/pharma industry including serving as the Advisory Member for the Asia-Pacific Economic Cooperation (APEC) Harmonization Center, Korean government delegate for APEC Life Science Innovation Forum, Healthcare division representative for Korea-US Business Council, and etc.

 

Moderator: Kimberly Ha

Founder, KKH Advisors

 

Kimberly Ha is the founder and CEO of KKH Advisors, a life sciences advisory firm. She was previously Senior Director at FTI Consulting, Healthcare Capital Markets Communications, where she advised a broad range of clients from Fortune 500 to early-stage development companies on business transformation, corporate and executive positioning, crisis and issues management, and financial communications. She is also a digital health advisor to Array Ventures, a VC fund based in San Francisco.

Vincent Liu, PhD

Senior Advisor, Fosun Pharma

 

Vincent Liu is the Senior Advisor of Fosun Pharma. He worked in International Business Division and Wanbang Biopharmaceutical of Shanghai Fosun Pharmaceutical Group in 2009. His achievements including helping the company to raise a $500 million private equity fund from oversea and setting up two joint ventures with large US and Canadian companies in China, investment in healthcare service company in the US and completed several pharmaceutical business development transactions which could potentially bring to Chinese market total over $1 billion revenue product opportunities in the future.

David Blume

Managing Director, Edgemont Capital Partners

 

David Blume has spent his entire 30-year professional career in investment banking with an exclusive focus on the healthcare industry. He has completed over 100 transactions, representing more than $30 billion in value, including mergers and acquisitions, fairness opinions, partnerships, joint ventures, public and private equity, and financial advisory services. His healthcare experience covers a broad range of industry sectors, including pharmaceuticals, pharmaceutical outsourcing (CROs, pharmaceutical sales and marketing companies), physician groups and care delivery, healthcare information technology, and many related areas.

John Bradley, MD

Managing Director, Torreya Partners

 

John Bradley is the Managing Director at Torreya, where he works with the firm’s financing and M&A businesses. He has a vast network of relationships in the life sciences industry as well as with family offices and high net worth individuals worldwide. An expert in branded pharmaceuticals and drug delivery, he has raised over $500 million in public and private capital for many pharmaceutical, insurance, and technology companies. John has more than 40 years of corporate finance experience as an executive within both pharmaceutical companies and investment banks. Prior to joining Torreya, he was also a Founder and President of NYSE firm Bradley-Hummel & Co., and VP at Drexel Burnham & Co.

Moderator: Joe McMenamin, MD, JD

EVP, W Medical Strategy Group

 

Joseph (Joe) P. McMenamin is an Executive Vice President and Chief Legal Officer with W Medical Strategy Group. He has more than 20 years of experience in defending pharmaceutical, medical device, and biotech companies in state and federal court. He also advises clients on managing risks related to telemedicine, corporate use of the internet, social media, communications between life science companies and physicians, compliance with FDA regulations.

Jeff Clark, MD, JD

Chief Licensing Officer, Enzychem Lifesciences

 

Jeff Clark is the Chief Licensing Officer at Enzychem Lifesciences, a Korean-based life sciences pharmaceutical company focusing on oncology, inflammatory and pulmonary diseases.  He develops the world-wide Intellectual Property (IP) Patent and Trademark portfolios.  He also collaborates and negotiates licensing and other agreements with third-parties regarding on-going clinical trials. He previously was an associate at the global law firm DLA Piper LLP (US), and was a clinical research fellow in the Molecular and Vascular Medicine Unit (Renal Division) at Beth Israel Deaconess Medical Center and a research fellow in the Cardiovascular Research Center at Massachusetts General Hospital.

Eunie Kim

Advisor, C&R Research

 

Eunie Kim is the director of W Medical Strategy Group and currently serves as the Project Director and Adviser for C&R Research, a major CRO company in South Korea. She has almost 20 years of experience in business strategy and management consulting for biomedical, healthcare, and medical devices companies. She also advises clients on managing their organization and system to achieve their highest business performance in the healthcare and finance industries. Eunie Kim holds a MS degree in Negotiation and Conflict Resolution from Columbia University in the City of New York and MBA from Korea University Business School.

John Choi, MS

Project Director, Enzychem Lifesciences

 

John Choi is currently Project Director for Enzychem Lifesciences. He has over 27 years of pharmaceutical industry experience centered in clinical operations management including P&L, project planning and resource management, regulatory services, training, business process and clinical development improvement, clinical trial management, medical device approvals, and quality assurance. Before joining Enzychem, he was a Protocol Manager, Oncology Clinical Protocol Operations at Syneos Heath Clinical Solutions working for Bristol-Myers Squibb project in NJ. He was president of Piscium International, Inc. and Chief Executive Officer for local Korea CRO Solomon Medical Research, Inc. He also served as Director of Clinical Operations APAC/Head of TS3 APAC/Country Head Korea for Theorem Clinical Research (now, Chiltern) in Seoul, Korea. He was Senior Manager, Clinical Consulting Barnett International/Parexel in US and Resource Manager, Global Clinical Operations for Bristol Myers Squibb Lawrenceville, NJ USA.

Surani Fernando

Editor, North America, Biopharm Insight

 

Surani Fernando manages the North America editorial desk. Since joining the London newsroom in 2010, Surani has generated a number of market-moving scoops and in-depth analyses on the drug development sector. Surani has covered academic and industry meetings in Europe and the US and has made TV appearances on CNBC and Sky News. Prior to journalism, she worked in clinical operations at CRO PAREXEL. She has a Bachelor of Medical Science and Master of Health Communication, both from Sydney University, Australia.

Scott Howell, MD, MPH&TM, CPE

Chief Medical Officer, Tenet Diagnostics

 

Scott Howell, is the Chief Medical Officer for Tenet Diagnostic, a comprehensive full service laboratory with concentration on clinical quality, population health and next generation genetic tests. He also is board certified in Family Practice, Preventative Medicine and Public Health and Addiction Medicine and has been in medicine for over 25 years.  He is certified by the American College of Physician Executives as a Certified Physician Executive (CPE) and has served the military for 25 years. His current reserve assignment is with the Office of Secretary of Defense (OSD) at the Department of Defense Inspector General (DoDIG) concentrating on the Wounded Warrior Program, BioAssurity, and Ebola Outbreak Assessment.

Anthony Chambers

Director, Life Sciences Practice, West Monroe Partners

 

Anthony Chambers is the Director in the Life Sciences Practice with West Monroe Partners, a business and technology advisory firm. He has more than 20 years of experience in management and technology consulting. He advises Pharmaceutical and Biotech clients on technology and information systems in R&D and laboratories. Previously, Anthony was a senior principal and IT Strategy service line lead with the Chicago branch of Daugherty Business Solutions, an IT management consultancy. He also spent five years with Diamond Management and Technology Consultants (acquired by PwC), advancing to the level of principal. His clients included leading global financial services, insurance, and consumer packaged goods organizations.